Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd (JENBURPH) last reported results for the quarter ended Jun 2026, with sales of ₹35.51 crore and net profit of ₹5.89 crore. The stock last traded at ₹901, a market capitalisation of ₹397 crore, on a P/E of 11.1. Over the past 52 weeks the stock has ranged between ₹892 and ₹1,321. Figures are as of 6 Oct 2026 and are not real time.
Jenburkt Pharmaceuticals Ltd share price and key metrics
- Current price
- ₹901
- Market cap
- ₹397 cr
- Stock P/E
- 11.1
- Book value
- ₹446
- ROE
- 20.2%
- ROCE
- 27.0%
- Dividend yield
- 2.30%
- 52w high / low
- 1321/892
Metrics as of 6 Oct 2026. Not real time.
Track Jenburkt Pharmaceuticals Ltd
Cruxal reads every Jenburkt Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Jenburkt Pharmaceuticals Ltd growth and returns
- 10 Years
- 6%
- 5 Years
- 9%
- 3 Years
- 7%
- TTM
- 9%
- 10 Years
- 13%
- 5 Years
- 18%
- 3 Years
- 15%
- TTM
- 10%
- 10 Years
- 10%
- 5 Years
- 13%
- 3 Years
- 10%
- 1 Year
- -14%
- 10 Years
- 21%
- 5 Years
- 20%
- 3 Years
- 20%
- Last Year
- 20%
Jenburkt Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹35.51 cr, down 0.1% from ₹35.53 cr a year earlier. Net profit was ₹5.89 cr, down 24.4% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 41.22 | 36.89 | 41.05 | 35.53 | 45.56 | 43.02 | 44.63 | 35.51 |
| Expenses | 29.79 | 28.07 | 30.19 | 26.58 | 32.45 | 35.59 | 30.38 | 29.48 |
| Operating profit | 11.43 | 8.82 | 10.86 | 8.95 | 13.11 | 7.43 | 14.25 | 6.03 |
| OPM % | 27.73% | 23.91% | 26.46% | 25.19% | 28.78% | 17.27% | 31.93% | 16.98% |
| Other income | 1.85 | 1.58 | 1.88 | 2.06 | 2.08 | 1.82 | 0.4 | 1.51 |
| Interest | 0.12 | 0.11 | 0.11 | 0.11 | 0.11 | 0.12 | 0.13 | 0.13 |
| Depreciation | 0.64 | 0.78 | 0.79 | 0.72 | 0.74 | 0.83 | 0.81 | 0.64 |
| Profit before tax | 12.52 | 9.51 | 11.84 | 10.18 | 14.34 | 8.3 | 13.71 | 6.77 |
| Tax % | 23.32% | 31.65% | 27.87% | 23.48% | 29.08% | 28.55% | 20.86% | 13.00% |
| Net profit | 9.6 | 6.51 | 8.54 | 7.79 | 10.16 | 5.93 | 10.85 | 5.89 |
| EPS (₹) | 21.75 | 14.75 | 19.35 | 17.65 | 23.02 | 13.44 | 24.58 | 13.35 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Jenburkt Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 103 | 115 | 123 | 119 | 109 | 124 | 137 | 142 | 152 | 169 | 169 |
| Operating profit | 20 | 24 | 25 | 20 | 20 | 27 | 30 | 33 | 40 | 44 | 41 |
| OPM % | 19% | 21% | 20% | 17% | 18% | 22% | 22% | 23% | 27% | 26% | 24% |
| Net profit | 14 | 17 | 20 | 15 | 16 | 22 | 25 | 26 | 32 | 35 | 33 |
| EPS (₹) | 29.06 | 37.50 | 43.14 | 32.40 | 35.95 | 48.59 | 55.76 | 58.87 | 72.64 | 78.72 | 74.39 |
TTM is the trailing twelve months to the most recent quarter.
Jenburkt Pharmaceuticals Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 |
| Reserves | 50 | 57 | 73 | 75 | 94 | 113 | 118 | 141 | 167 | 193 |
| Borrowings | 6 | 0 | 7 | 3 | 5 | 7 | 3 | 0 | 4 | 2 |
| Other liabilities | 16 | 16 | 18 | 21 | 17 | 18 | 16 | 19 | 19 | 26 |
| Total liabilities | 76 | 77 | 103 | 104 | 120 | 143 | 141 | 164 | 195 | 225 |
| Fixed assets | 11 | 10 | 10 | 12 | 11 | 11 | 10 | 10 | 15 | 19 |
| CWIP | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 40 | 46 |
| Investments | 2 | 5 | 5 | 4 | 7 | 8 | 11 | 17 | 21 | 27 |
| Other assets | 64 | 62 | 87 | 88 | 103 | 123 | 119 | 136 | 120 | 132 |
| Total assets | 76 | 77 | 103 | 104 | 120 | 143 | 141 | 164 | 195 | 225 |
As reported by the company. Total assets equal total liabilities by construction.
Jenburkt Pharmaceuticals Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 10 | 16 | 13 | 15 | 19 | 9 | 17 | 8 | 28 | 27 |
| Cash from investing | -10 | 1 | -11 | -3 | -19 | -1 | 3 | -1 | -17 | -19 |
| Cash from financing | 1 | -18 | -2 | -11 | -1 | -6 | -21 | -7 | -8 | -9 |
| Net cash flow | 1 | -1 | 0 | 1 | -0 | 3 | -1 | 0 | 3 | -2 |
| Free cash flow | 10 | 16 | 11 | 11 | 18 | 7 | 15 | 6 | 8 | 13 |
| CFO / operating profit | 85% | 103% | 80% | 104% | 127% | 62% | 83% | 49% | 102% | 88% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Jenburkt Pharmaceuticals Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 39% | 42% | 37% | 26% | 24% | 26% | 27% | 26% | 27% | 27% |
| Debtor days | 32 | 40 | 68 | 55 | 47 | 45 | 45 | 50 | 50 | 53 |
| Inventory days | 128 | 73 | 99 | 120 | 92 | 115 | 92 | 103 | 109 | 154 |
| Days payable | 72 | 44 | 66 | 58 | 56 | 83 | 67 | 75 | 100 | 91 |
| Cash conversion cycle | 89 | 69 | 101 | 117 | 83 | 77 | 70 | 78 | 59 | 115 |
| Working capital days | 10 | 25 | 35 | 32 | 17 | 16 | 31 | 36 | 31 | 41 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Jenburkt Pharmaceuticals Ltd shareholding pattern
Promoters held 46.62% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.00% and DIIs 0.12%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 46.71% | 46.69% | 46.68% | 46.67% | 46.66% | 46.65% | 46.64% | 46.62% |
| FIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DIIs | 0.00% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% |
| Public | 53.28% | 53.20% | 53.20% | 53.21% | 53.22% | 53.24% | 53.24% | 53.27% |
| No. of shareholders | 6,628 | 6,901 | 6,987 | 6,712 | 6,855 | 7,163 | 6,999 | 7,103 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Jenburkt Pharmaceuticals Ltd corporate filings
- Jenburkt Pharmaceuticals Ltd equity shares admitted under 'Permitted to Trade' category on NSECompany Updatelow impact
Cruxal's analysis: Jenburkt Pharmaceuticals Ltd has announced that its equity shares have been admitted…
Read the full analysis - Intimation of closure of trading window of the Jenburkt Pharmaceuticals Limited as per the SEBI(Prohibition of Insider Trading) Regulations, 2015.Insider Trading / SASTlow impact
- Jenburkt Pharmaceuticals announces resignation of Senior Vice President - International BusinessCompany Updatelow impact
Cruxal's analysis: Jenburkt Pharmaceuticals Limited has announced the resignation of Mr. Vinay Bhatt, Senior…
Read the full analysis - Jenburkt Pharmaceuticals announces elevation of Prem Ashish Bhuta to Associate Vice President – Strategic InitiativesCompany Updatelow impact
Cruxal's analysis: Jenburkt Pharmaceuticals Limited has announced the promotion of Prem Ashish Bhuta to the…
Read the full analysis - Jenburkt Pharmaceuticals Limited: Newspaper Publication of Financial Results for Quarter Ended 30 June 2026Company Updatelow impact
Cruxal's analysis: Jenburkt Pharmaceuticals Limited has fulfilled its regulatory obligation under SEBI…
Read the full analysis - Jenburkt Pharmaceuticals reports Q1 FY27 earnings with significant YoY decline in profitabilityBoard Meetinghigh impact
Cruxal's analysis: Jenburkt Pharmaceuticals Limited reported a challenging first quarter for FY27, with…
Read the full analysis - Jenburkt Pharmaceuticals Announces 41st Annual General Meeting on September 4, 2026, Completes Annual Report DispatchCompany Updatelow impact
Cruxal's analysis: Jenburkt Pharmaceuticals Limited has announced the scheduling of its 41st Annual General…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.